KR102532944B1 - Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine mixture extract as effective component - Google Patents
Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine mixture extract as effective component Download PDFInfo
- Publication number
- KR102532944B1 KR102532944B1 KR1020220048905A KR20220048905A KR102532944B1 KR 102532944 B1 KR102532944 B1 KR 102532944B1 KR 1020220048905 A KR1020220048905 A KR 1020220048905A KR 20220048905 A KR20220048905 A KR 20220048905A KR 102532944 B1 KR102532944 B1 KR 102532944B1
- Authority
- KR
- South Korea
- Prior art keywords
- parts
- weight
- composition
- sars
- cov2
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 239000000284 extract Substances 0.000 title claims abstract description 49
- 208000001528 Coronaviridae Infections Diseases 0.000 title abstract description 27
- 241000411851 herbal medicine Species 0.000 title abstract description 4
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 title 1
- 235000013376 functional food Nutrition 0.000 claims abstract description 15
- 230000036541 health Effects 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 208000015181 infectious disease Diseases 0.000 claims abstract description 7
- 239000003674 animal food additive Substances 0.000 claims abstract description 5
- 241000315672 SARS coronavirus Species 0.000 claims description 40
- 239000004480 active ingredient Substances 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 15
- 239000000454 talc Substances 0.000 claims description 14
- 229910052623 talc Inorganic materials 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 241000212948 Cnidium Species 0.000 claims description 10
- 241000218671 Ephedra Species 0.000 claims description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 10
- 244000299790 Rheum rhabarbarum Species 0.000 claims description 10
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 10
- 230000000840 anti-viral effect Effects 0.000 claims description 10
- 239000010440 gypsum Substances 0.000 claims description 10
- 229910052602 gypsum Inorganic materials 0.000 claims description 10
- 229940010454 licorice Drugs 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 9
- 244000170916 Paeonia officinalis Species 0.000 claims description 9
- 244000273928 Zingiber officinale Species 0.000 claims description 9
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 9
- 235000008397 ginger Nutrition 0.000 claims description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 9
- 239000010931 gold Substances 0.000 claims description 9
- 229910052737 gold Inorganic materials 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 8
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 8
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 8
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 240000002045 Guettarda speciosa Species 0.000 claims description 7
- 241000286209 Phasianidae Species 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims 5
- 241000202807 Glycyrrhiza Species 0.000 claims 5
- 241000893011 Tamaricaceae Species 0.000 claims 5
- 235000010185 Tamarix canariensis Nutrition 0.000 claims 5
- 235000014265 Tamarix gallica Nutrition 0.000 claims 5
- 235000010154 Tamarix ramosissima Nutrition 0.000 claims 5
- 239000009520 bofu-tsusho-san Substances 0.000 abstract description 35
- 241000700605 Viruses Species 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 7
- 239000002537 cosmetic Substances 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 4
- -1 for example Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 241000711573 Coronaviridae Species 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 240000004670 Glycyrrhiza echinata Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 4
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000711466 Murine hepatitis virus Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 240000005893 Pteridium aquilinum Species 0.000 description 1
- 235000009936 Pteridium aquilinum Nutrition 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 238000011598 SARS-CoV-2 infection animal model Methods 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 복합한약재 추출물, 특히 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for the prevention, improvement or treatment of coronavirus infection comprising a composite herbal medicine extract, particularly a bangpungtongseongsan extract as an active ingredient.
신종 제2형 중증급성호흡기증후군 코로나바이러스(SARS-CoV2)는 약 3만 개의 염기쌍으로 이루어진 단일 가닥의 양성 RNA 게놈을 가지고 있고, 바이러스 표면이 외피로 둘러싸여 있는 바이러스이다. 2019년 12월 말에 중국 우한에서 최초로 보고된 후 전 세계적으로 감염자가 폭증하였다. 상기 바이러스는 사람 사이의 전파가 매우 효율적으로 이루어져 세계보건기구에서도 전 세계에 유행이 가능한 펜데믹으로 선포하고 대응을 모색하고 있다.The
일반적인 코비드-19 환자는 체온상승, 기침 및 가슴 통증과 같은 비교적 심하지 않은 증상을 보이지만, 일부 환자에게서는 호흡곤란 및 폐렴과 같은 심각한 질환으로 발전되어 사망에 이르게 된다. Normal Covid-19 patients show relatively mild symptoms such as elevated body temperature, coughing and chest pain, but some patients develop serious illnesses such as shortness of breath and pneumonia, leading to death.
현재까지 코로나바이러스 감염증에 대해 공인된 치료제로는 리바비린(ribavirin), 팜시클로비르(famciclovir), 니타족사나이드(nitazoxanide), 나파모스타트(nafamostat) 및 클로로퀸(chloroquine) 등이 알려져 있으며, 이외에도 렘데시비르(remdesivir, GS-5734)와 파비피라비르(favipiravir)가 코로나바이러스 감염증 치료에 사용되고 있으나, 효과가 낮고 핵산 아날로그형 항바이러스제들의 특성상 변종바이러스의 발생율이 높아 2종 이상의 항바이러스제를 같이 적용하고 있다. 코로나바이러스 감염증에 사용되는 항바이러스제들은 대부분 RNA 폴리머라아제(polymerase) 억제능을 가지고 있지만, 렘데시비르에 대한 내성을 가지는 코로나바이러스의 일종인 마우스 간염 바이러스(Mouse hepatitis virus)가 발견되었으며, 기존의 항바이러스제의 효과가 없는 실정이다. 또한, 현재까지 개발된 항바이러스제들은 심한 부작용을 나타내고 있으므로, 그 응용에 있어서 많은 주의가 필요하다. To date, approved treatments for coronavirus infections include ribavirin, famciclovir, nitazoxanide, nafamostat, and chloroquine. In addition, remdesi Vir (remdesivir, GS-5734) and favipiravir are used for the treatment of coronavirus infections, but their effectiveness is low and the incidence of mutant viruses is high due to the nature of nucleic acid analog antiviral agents, so two or more antiviral agents are applied together. . Most of the antiviral drugs used for coronavirus infection have RNA polymerase inhibitory ability, but Mouse hepatitis virus, a type of coronavirus resistant to remdesivir, was discovered, and the existing antiviral The current situation is that there is no effect of the virus agent. In addition, since antiviral agents developed to date have severe side effects, great care is required in their application.
또한, 현재 가장 일반적인 치료 방법은 증상을 완화하는 대증요법이다. 따라서 코로나바이러스의 발생을 예방하고 치료하기 위한 감염 억제 효과가 뛰어나고 독성이 적은 새로운 항코로나바이러스제의 개발 필요성이 증가되고 있다.In addition, the most common treatment method at present is symptomatic therapy to relieve symptoms. Therefore, there is an increasing need for the development of new anti-coronavirus agents with excellent infection suppression effect and low toxicity for preventing and treating the outbreak of coronavirus.
한편, 한국공개특허 제2022-0013625호에는 울괴불나무 추출물을 유효성분으로 포함하는 것을 특징으로 하는 항코로나바이러스 조성물이 개시되어 있고, 한국공개특허 제2022-0018953호에는 고사리 추출물 또는 이의 분획물을 포함하는 항바이러스용 조성물이 개시되어 있지만, 본 발명의 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물에 관해 전혀 개시된 바 없다. On the other hand, Korean Patent Publication No. 2022-0013625 discloses an anti-coronavirus composition characterized in that it contains an extract of euphorbia nigra as an active ingredient, and Korean Patent Publication No. 2022-0018953 includes a bracken extract or a fraction thereof. Although an antiviral composition is disclosed, there is no disclosure of a composition for preventing, improving or treating coronavirus infection comprising the extract of Bangpungtongseongsan as an active ingredient.
본 발명은 상기와 같은 요구에 의해 도출된 것으로, 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스에 대한 항바이러스용 조성물을 제공하고, 상기 추출물이 코로나바이러스 감염으로부터 세포를 보호하고, 바이러스 증식을 억제하며, 코로나바이러스 감염 동물모델에서 감염에 의한 치사율을 감소시키는 것을 확인함으로써, 본 발명을 완성하였다.The present invention has been derived from the above needs, and provides an antiviral composition against coronavirus comprising an extract of Bangpungtongseongsan as an active ingredient, wherein the extract protects cells from coronavirus infection and inhibits viral proliferation. And, the present invention was completed by confirming that the mortality rate due to infection was reduced in a coronavirus-infected animal model.
상기 과제를 해결하기 위하여, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스에 대한 항바이러스용 조성물을 제공한다. In order to solve the above problems, the present invention provides an antiviral composition for coronavirus comprising Bangpungtongseongsan extract as an active ingredient.
또한, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학 조성물을 제공한다. In addition, the present invention provides a pharmaceutical composition for preventing or treating coronavirus infection comprising an extract of Bangpungtongseongsan as an active ingredient.
또한, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for preventing or improving coronavirus infection comprising Bangpungtongseongsan extract as an active ingredient.
또한, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 의약외품 조성물을 제공한다. In addition, the present invention provides a quasi-drug composition for preventing or improving coronavirus infection comprising Bangpungtongseongsan extract as an active ingredient.
또한, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for preventing or improving coronavirus infection comprising an extract of Bangpungtongseongsan as an active ingredient.
또한, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 사료 첨가제를 제공한다.In addition, the present invention provides a feed additive for the prevention or improvement of coronavirus infection comprising Bangpungtongseongsan extract as an active ingredient.
본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물에 관한 것으로, 방풍통성산 추출물은 코로나바이러스 감염으로부터 세포를 보호하고, 바이러스의 증식을 억제하며, 코로나바이러스 감염 동물모델에서 감염에 의한 치사율을 감소시키는 효과가 있다.The present invention relates to a composition for preventing, ameliorating or treating a coronavirus infection comprising an extract of Bangpungtongseongsan as an active ingredient, wherein the extract of Bangpungtongseongsan protects cells from coronavirus infection, inhibits the proliferation of the virus, and prevents coronavirus infection It has the effect of reducing mortality due to infection in animal models.
도 1은 방풍통성산 추출물의 SARS-CoV2에 대한 항바이러스 효과를 CPE(Cytopathic effect) 억제 분석으로 확인한 것으로, 농도별 방풍통성산 추출물 처리에 따른 SARS-CoV2에 대한 항바이러스 효과를 크리스탈 바이올렛으로 염색한 플레이트 사진(A) 및 이를 정량한 결과(B)이다. NC는 정상군이고, VC는 SARS-CoV2를 처리한 대조군이다. ****은 SARS-CoV2를 처리한 대조군(VC) 대비 방풍통성산 추출물 처리군의 세포 병변 감소율이 통계적으로 유의미하게 증가하였다는 것을 의미하며, ****은 p<0.0001이다.
도 2는 SARS-CoV2 감염 동물모델에서 방풍통성산 추출물 투여에 따른 체중(A), 체온(B) 및 생존률(C)을 확인한 결과이다. Mock은 SARS-CoV2에 감염되지 않은 정상군이고, Control은 SARS-CoV2 감염군이며, SARS-CoV2+방풍통성산 추출물은 SARS-CoV2 감염 및 본 발명의 방풍통성산을 투여한 군이다. Figure 1 confirms the antiviral effect of Bangpungtongseongsan extract against SARS-CoV2 by CPE (Cytopathic effect) inhibition analysis, plate stained with crystal violet for antiviral effect against SARS-CoV2 according to Bangpungtongseongsan extract treatment by concentration It is a photograph (A) and the result of quantifying it (B). NC is a normal group, and VC is a control group treated with SARS-CoV2. **** means that the cell lesion reduction rate of the Bangpungtongseongsan extract-treated group compared to the control group (VC) treated with SARS-CoV2 was statistically significantly increased, and **** is p<0.0001.
Figure 2 is the result of confirming the body weight (A), body temperature (B) and survival rate (C) according to the administration of bangpungtongseongsan extract in the SARS-CoV2 infected animal model. Mock is a normal group not infected with SARS-CoV2, Control is a SARS-CoV2 infected group, and SARS-CoV2 + Bangpungtongseong acid extract is a group infected with SARS-CoV2 and administered Bangpungtongseongsan of the present invention.
본 발명의 목적을 달성하기 위하여, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스에 대한 항바이러스용 조성물을 제공한다. In order to achieve the object of the present invention, the present invention provides an antiviral composition for coronavirus comprising Bangpungtongseongsan extract as an active ingredient.
상기 코로나바이러스는 제2형 중증급성호흡기증후군 코로나바이러스(SARS-CoV2), 중증급성호흡기증후군 코로나바이러스(SARS CoV) 및 중동 호흡기 증후군(MERS) 코로나바이러스로 이루어진 군에서 선택된 1종 이상인 것일 수 있고, 바람직하게는 제2형 중증급성호흡기증후군 코로나바이러스(SARS-CoV2)인 것이지만, 이에 한정하는 것은 아니다. The coronavirus may be one or more selected from the group consisting of
본 발명의 일 구현 예에서, 상기 방풍통성산은 당귀, 작약, 천궁, 산치자, 연교, 박하, 생강, 형개, 방풍, 마황, 대황, 건조망초, 백출, 길경, 황금, 감초, 석고 및 활석의 혼합물일 수 있고, 바람직하게는 0.6~2.4 중량부의 당귀, 0.6~2.4 중량부의 작약, 0.6~2.4 중량부의 천궁, 0.6~2.4 중량부의 산치자, 0.6~2.4 중량부의 연교, 0.6~2.4 중량부의 박하, 0.2~0.8 중량부의 생강, 0.6~2.4 중량부의 형개, 0.6~2.4 중량부의 방풍, 0.6~2.4 중량부의 마황, 0.75~3.0 중량부의 대황, 0.375~1.5 중량부의 건조망초, 1.0~4.0 중량부의 백출, 1.0~4.0 중량부의 길경, 1.0~4.0 중량부의 황금, 1.0~4.0 중량부의 감초, 1.0~4.0 중량부의 석고 및 1.5~6.0 중량부의 활석으로 이루어진 혼합물이며, 더 바람직하게는 1.0~1.4 중량부의 당귀, 1.0~1.4 중량부의 작약, 1.0~1.4 중량부의 천궁, 1.0~1.4 중량부의 산치자, 1.0~1.4 중량부의 연교, 1.0~1.4 중량부의 박하, 0.3~0.5 중량부의 생강, 1.0~1.4 중량부의 형개, 1.0~1.4 중량부의 방풍, 1.0~1.4 중량부의 마황, 1.3~1.7 중량부의 대황, 0.5~1.0 중량부의 건조망초, 1.5~3.0 중량부의 백출, 1.5~3.0 중량부의 길경, 1.5~3.0 중량부의 황금, 1.5~3.0 중량부의 감초, 1.5~3.0 중량부의 석고 및 2~4 중량부의 활석으로 이루어진 혼합물이며, 가장 바람직하게는 1.2 중량부의 당귀, 1.2 중량부의 작약, 1.2 중량부의 천궁, 1.2 중량부의 산치자, 1.2 중량부의 연교, 1.2 중량부의 박하, 0.4 중량부의 생강, 1.2 중량부의 형개, 1.2 중량부의 방풍, 1.2 중량부의 마황, 1.5 중량부의 대황, 0.75 중량부의 건조망초, 2.0 중량부의 백출, 2.0 중량부의 길경, 2.0 중량부의 황금, 2.0 중량부의 감초, 2.0 중량부의 석고 및 3.0 중량부의 활석으로 이루어진 혼합물인 것이지만, 이에 제한하는 것은 아니다. In one embodiment of the present invention, the Bangpungtongseongsan is a mixture of Angelica, Peony, Cnidium, Sanchija, Yeongyo, Mint, Ginger, Hyeonggae, Bangpung, Ephedra, Rhubarb, Dried Forget-me-not, Baekchul, Longgyeong, Golden, Licorice, Gypsum and Talc. may, preferably 0.6 to 2.4 parts by weight of Angelica gigas, 0.6 to 2.4 parts by weight of Peony, 0.6 to 2.4 parts by weight of Cnidium, 0.6 to 2.4 parts by weight of Gardenia, 0.6 to 2.4 parts by weight of Yeongyo, 0.6 to 2.4 parts by weight of mint, 0.2 to 2.4 parts by weight 0.8 parts by weight of ginger, 0.6 to 2.4 parts by weight of mould, 0.6 to 2.4 parts by weight of windbreak, 0.6 to 2.4 parts by weight of ephedra, 0.75 to 3.0 parts by weight of rhubarb, 0.375 to 1.5 parts by weight of dry nettleweed, 1.0 to 4.0 parts by weight of baekchul, 1.0 to It is a mixture consisting of 4.0 parts by weight of ginseng, 1.0 to 4.0 parts by weight of gold, 1.0 to 4.0 parts by weight of licorice, 1.0 to 4.0 parts by weight of gypsum, and 1.5 to 6.0 parts by weight of talc, more preferably 1.0 to 1.4 parts by weight of Angelica quail, 1.0 to 4.0 parts by weight. 1.4 parts by weight of peony, 1.0 to 1.4 parts by weight of Cnidium, 1.0 to 1.4 parts by weight of Sanchija, 1.0 to 1.4 parts by weight of Yeongyo, 1.0 to 1.4 parts by weight of mint, 0.3 to 0.5 parts by weight of ginger, 1.0 to 1.4 parts by weight of mold, 1.0 to 1.4 parts by weight Windbreak by weight, 1.0 to 1.4 parts by weight ephedra, 1.3 to 1.7 parts by weight of rhubarb, 0.5 to 1.0 parts by weight of dry nettleweed, 1.5 to 3.0 parts by weight of baekchul, 1.5 to 3.0 parts by weight of gilgyeong, 1.5 to 3.0 parts by weight of gold, 1.5 to 3.0 parts by weight It is a mixture consisting of licorice by weight, 1.5 to 3.0 parts by weight of gypsum, and 2 to 4 parts by weight of talc, most preferably 1.2 parts by weight of Angelica quail, 1.2 parts by weight of Peony, 1.2 parts by weight of Cnidium, 1.2 parts by weight of Sanchija, and 1.2 parts by weight of Yeongyo. , 1.2 parts by weight of peppermint, 0.4 parts by weight of ginger, 1.2 parts by weight of mould, 1.2 parts by weight of windbreak, 1.2 parts by weight of ephedra, 1.5 parts by weight of rhubarb, 0.75 parts by weight of dried nettle grass, 2.0 parts by weight of baekchul, 2.0 parts by weight of gyeonggi, 2.0 parts by weight A mixture consisting of gold, 2.0 parts licorice, 2.0 parts gypsum and 3.0 parts talc, but is not limited thereto.
본 발명의 방풍통성산 추출물은 제2형 중증급성호흡기증후군 코로나바이러스의 증식을 억제하는 효과가 있다. Bangpungtongseong acid extract of the present invention has the effect of inhibiting the proliferation of
또한, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학 조성물을 제공한다. In addition, the present invention provides a pharmaceutical composition for preventing or treating coronavirus infection comprising an extract of Bangpungtongseongsan as an active ingredient.
본 발명에 따른 상기 약학 조성물은 각각 통상의 방법에 따라 캡슐제, 산제, 과립제, 정제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. The pharmaceutical composition according to the present invention is formulated according to conventional methods into oral formulations such as capsules, powders, granules, tablets, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions. can
본 발명에 따른 상기 약학 조성물은 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더 포함할 수 있다. The pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent.
본 발명의 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한 다양한 화합물 혹은 혼합물을 들 수 있다. Carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate , cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and various compounds or mixtures including mineral oil and the like.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 약학 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당하는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로골, 트윈 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include at least one excipient in the pharmaceutical composition, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. is prepared by mixing In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions for oral use, emulsions, syrups, etc., and various excipients such as wetting agents, sweeteners, aromatics, preservatives, etc. may be included in addition to water and liquid paraffin, which are commonly used simple diluents. . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, Witepsol, Macrogol, Tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.
본 발명의 약학 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. A suitable dosage of the pharmaceutical composition of the present invention will be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, morbid condition, food, administration time, administration route, excretion rate and reaction sensitivity. can
본 발명의 약학 조성물은 경구 또는 비경구로 투여할 수 있으며, 비경구투여의 경우, 피부에 국소적으로 도포, 정맥 내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있다.The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by topical application to the skin, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, and the like.
또한, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for preventing or improving coronavirus infection comprising Bangpungtongseongsan extract as an active ingredient.
상기 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조될 수 있지만, 이에 한정하는 것은 아니다. The composition may be prepared in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage, but is not limited thereto.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 양은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 총 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취인 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When using the health functional food composition of the present invention as a food additive, the health functional food composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to conventional methods. The amount of the active ingredient can be appropriately used depending on the purpose of its use (prevention or improvement). In general, when preparing food or beverage, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the total amount of raw materials. However, in the case of long-term intake for health purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the type of health functional food. Examples of foods to which the health functional food composition can be added include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea There are drinks, alcoholic beverages, and vitamin complexes, and includes all health foods in a conventional sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함할 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.In addition, the health functional food composition of the present invention can be made into food, particularly functional food. The functional food of the present invention includes components commonly added during food preparation, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, when prepared as a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to active ingredients. The natural carbohydrate is a monosaccharide (eg, glucose, fructose, etc.), a disaccharide (eg, maltose, sucrose, etc.), an oligosaccharide, a polysaccharide (eg, dextrin, cyclodextrin, etc.) or a sugar alcohol (eg, For example, xylitol, sorbitol, erythritol, etc.) is preferable. As the flavoring agent, natural flavoring agents (eg, thaumatin, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) may be used.
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the health functional food composition, various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonic acid It may further contain a carbonation agent used in beverages and the like. The ratio of the components to be added is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
또한, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 의약외품 조성물을 제공한다. In addition, the present invention provides a quasi-drug composition for preventing or improving coronavirus infection comprising Bangpungtongseongsan extract as an active ingredient.
상기 의약외품은 피부외용제 및 개인위생용품을 포함할 수 있다. 예를 들어, 소독청결제, 샤워폼, 가그린, 물티슈, 세제비누, 핸드워시, 또는 연고제일 수 있으나 이에 제한되지는 않는다.The quasi-drugs may include external skin preparations and personal hygiene products. For example, it may be a disinfectant cleanser, shower foam, gargreen, wet tissue, detergent soap, hand wash, or ointment, but is not limited thereto.
본 발명에 따른 상기 의약외품 조성물을 의약외품 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 의약외품 또는 의약외품 성분과 함께 사용 할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효성분의 혼합량은 사용 목적에 따라 적합하게 결정될 수 있다.When the quasi-drug composition according to the present invention is used as a quasi-drug additive, the composition may be added as it is or used together with other quasi-drugs or quasi-drug ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use.
본 발명의 의약외품 조성물은 일 예로, 일반적인 유화 제형 및 가용화 제형의 형태로 제조된 것일 수 있다. 예를 들어, 로션 등과 같은 유액, 크림, 연고, 스프레이, 오일젤, 젤, 오일, 에어로졸과 같은 제형을 가질 수 있으나, 본 발명의 코로나바이러스 감염증의 예방 또는 개선 효과를 나타내는 것이라면 제한되지 않고 사용할 수 있다. The quasi-drug composition of the present invention may be prepared in the form of, for example, a general emulsified formulation and a solubilized formulation. For example, it may have formulations such as emulsions, creams, ointments, sprays, oil gels, gels, oils, and aerosols such as lotions, but it may be used without limitation as long as it exhibits the effect of preventing or improving coronavirus infection of the present invention. there is.
또한, 상기 의약외품 조성물은 각각의 제형에 일반적으로 의약외품 조성물에 배합되는 유분, 물, 계면활성제, 보습제, 탄소수 1 내지 4의 저급 알코올, 증점제, 킬레이트제, 색소, 방부제 또는 향료 등을 필요에 따라 적절히 배합하여 사용할 수 있다.In addition, the quasi-drug composition may appropriately contain oil, water, a surfactant, a moisturizer, a lower alcohol having 1 to 4 carbon atoms, a thickener, a chelating agent, a colorant, a preservative, or a flavoring agent, which are generally formulated in quasi-drug compositions, in each dosage form. Can be used in combination.
또한, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for preventing or improving coronavirus infection comprising an extract of Bangpungtongseongsan as an active ingredient.
본 발명의 화장료 조성물은 상기 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들이 포함되며, 예켠대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The cosmetic composition of the present invention includes components commonly used in cosmetic compositions in addition to the extract, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and conventional adjuvants such as carriers.
본 발명의 화장료 조성물은 당 업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수(스킨), 영양 화장수(밀크로션), 영양 크림, 맛사지 크림, 에센스, 아이크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 샴푸, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared in any formulation conventionally prepared in the art, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , It may be formulated as an oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it may be formulated into a flexible lotion (skin), nourishing lotion (milk lotion), nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, shampoo, pack, spray or powder. can
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라가칸타, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. are used as carrier components. It can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane / May contain a propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butyl glycol oil, fatty acid esters of glycerol, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라가칸타 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Star cellulose, aluminum metahydroxide, bentonite, agar or tragacantha and the like may be used.
본 발명의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is surfactant-containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
또한, 본 발명은 방풍통성산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 사료 첨가제를 제공한다. In addition, the present invention provides a feed additive for the prevention or improvement of coronavirus infection comprising Bangpungtongseongsan extract as an active ingredient.
본 발명의 사료 첨가제는 사료관리법상의 보조사료에 해당한다. 본 발명에서 용어 '사료'는 동물이 먹고, 섭취하며, 소화시키기 위한 또는 이에 적당한 임의의 천연 또는 인공 규정식, 한끼식 등 또는 상기 한끼식의 성분을 의미할 수 있다. 상기 사료의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용되는 사료를 사용할 수 있다. 상기 사료의 비제한적인 예로는, 곡물류, 근과류, 식품 가공 부산물류, 조류, 섬유질류, 제약 부산물류, 유지류, 전분류, 박류 또는 곡물 부산물류 등과 같은 식물성 사료; 단백질류, 무기물류, 유지류, 광물성류, 유지류, 단세포 단백질류, 동물성 플랑크톤류 또는 음식물 등과 같은 동물성 사료를 들 수 있다. 이들은 단독으로 사용되거나 2종 이상을 혼합하여 사용될 수 있다.The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act. In the present invention, the term 'feed' may refer to any natural or artificial diet, one meal, etc., or a component of the one meal meal, suitable for or suitable for consumption by animals. The type of feed is not particularly limited, and feeds commonly used in the art may be used. Non-limiting examples of the feed include vegetable feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal or grain by-products; Animal feed such as proteins, inorganic materials, oils, mineral oils, oils, single cell proteins, zooplankton, or food may be mentioned. These may be used alone or in combination of two or more.
이하, 제조예 및 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 제조예 및 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다. Hereinafter, the present invention will be described in more detail using preparation examples and examples. These Preparation Examples and Examples are only for explaining the present invention in more detail, and it is obvious to those skilled in the art that the scope of the present invention is not limited thereto.
제조예 1. 방풍통성산 추출물의 제조Preparation Example 1. Preparation of Bangpungtongseongsan Extract
본 발명에 사용된 방풍통성산은 1.2 중량부의 당귀, 1.2 중량부의 작약, 1.2 중량부의 천궁, 1.2 중량부의 산치자, 1.2 중량부의 연교, 1.2 중량부의 박하, 0.4 중량부의 생강, 1.2 중량부의 형개, 1.2 중량부의 방풍, 1.2 중량부의 마황, 1.5 중량부의 대황, 0.75 중량부의 건조망초, 2.0 중량부의 백출, 2.0 중량부의 길경, 2.0 중량부의 황금, 2.0 중량부의 감초, 2.0 중량부의 석고 및 3.0 중량부의 활석으로 이루어진 복합한약재 추출물을 크라시에 약품 유한회사(Kracie Pharma Ltd., JAPAN)로부터 제공받았다.Bangpungtongseongsan used in the present invention is 1.2 parts by weight of angelica, 1.2 parts by weight of peony, 1.2 parts by weight of Cnidium, 1.2 parts by weight of Sanchija, 1.2 parts by weight of Yeongyo, 1.2 parts by weight of mint, 0.4 parts by weight of ginger, 1.2 parts by weight of mold, 1.2 parts by weight A composite consisting of windbreak, 1.2 parts of ephedra, 1.5 parts of rhubarb, 0.75 parts of dry nettleweed, 2.0 parts of baekchul, 2.0 parts of gilgyeong, 2.0 parts of gold, 2.0 parts of licorice, 2.0 parts of gypsum and 3.0 parts of talc. Herbal medicine extracts were provided by Kracie Pharma Ltd., JAPAN.
실시예 1. CPE(cytopathic effect) 억제 분석을 통한 방풍통성산 추출물의 항바이러스 활성 확인Example 1. Confirmation of antiviral activity of Bangpungtongseongsan extract through CPE (cytopathic effect) inhibition assay
96웰 플레이트에 Vero E6 세포를 배양한 후, SARS-CoV2를 m.o.i 0.01로 접종하였다. 접종 후, 처리 농도에 맞도록 2%(v/v) FBS 및 1%(v/v) 페니실린-스트렙토마이신이 포함된 DMEM으로 희석하여 준비한 상기 제조예 1의 방풍통성산을 농도별로 처리한 다음, 3일 동안 배양하였다. 배양 후, 세포 배양액을 제거한 다음 메탄올:아세톤이 1:1 부피비로 혼합된 용액을 처리한 다음 실온에서 10분 동안 고정하였다. 이후, 용액을 제거하고, 0.4%(w/v) 크리스탈 바이올렛(crystal violet)을 각 웰에 첨가한 다음 10분 동안 실온에서 염색한 후, 용액을 모두 제거하고 건조하였다. 건조 후, 메탄올:아세트산을 1:1 부피비로 혼합한 다음 이를 3차 증류수로 5배 희석한 용액을 각 웰에 100㎕씩 첨가한 후 2시간 동안 크리스탈 바이올렛을 추출하였고, 이의 흡광도를 550nm에서 측정하였다. After culturing Vero E6 cells in a 96-well plate, SARS-CoV2 was inoculated with m.o.i 0.01. After inoculation, Bangpungtongseong acid of Preparation Example 1 prepared by diluting with DMEM containing 2% (v / v) FBS and 1% (v / v) penicillin-streptomycin to match the treatment concentration was treated by concentration, Cultured for 3 days. After incubation, the cell culture medium was removed and treated with a mixed solution of methanol:acetone in a volume ratio of 1:1, followed by fixation at room temperature for 10 minutes. Thereafter, the solution was removed, and 0.4% (w/v) crystal violet was added to each well, followed by staining at room temperature for 10 minutes, and then the solution was removed and dried. After drying, methanol:acetic acid was mixed at a volume ratio of 1:1, and then 100 μl of a solution diluted 5 times with tertiary distilled water was added to each well, and crystal violet was extracted for 2 hours, and its absorbance was measured at 550 nm did
그 결과, 도 1에 개시된 바와 같이 본 발명의 10~500㎍/㎖의 방풍통성산 추출물을 처리한 경우, SARS-CoV2의 증식을 억제하였고, IC50 값이 302.3㎍/㎖이었으므로, 본 발명의 방풍통성산 추출물은 SARS-CoV2 바이러스로부터 세포를 보호하고, 바이러스의 증식을 억제하는 항바이러스 효과가 우수하였다. As a result, as shown in FIG. 1, when 10 to 500 μg/ml of Bangpungtongseong acid extract of the present invention was treated, the proliferation of SARS-CoV2 was inhibited, and the IC 50 value was 302.3 μg/ml. The acid extract had an excellent antiviral effect of protecting cells from the SARS-CoV2 virus and inhibiting the proliferation of the virus.
실시예 2. SARS-CoV2 감염 동물모델에서 방풍통성산 추출물의 효능 평가Example 2. Efficacy evaluation of Bangpungtongseongsan extract in SARS-CoV2 infection animal model
hACE2 형질전환 마우스 모델에서 SARS-CoV2 감염에 대한 억제 효능을 평가하기 위하여, SARS-CoV2 감염시키기 2일 전부터 사망하는 날까지 방풍통성산 추출물을 1일 1회 경구 투여하였다. 감염 당일(0일째) 본 발명의 방풍통성산 추출물을 경구 투여하고 1시간 후, SARS-CoV2를 2,000pfu/mouse로 비강 접종하여 감염시켰고(20㎕/mouse), 실험 종료 9일 째까지 매일 체중 및 체온을 측정하였다.In order to evaluate the inhibitory effect on SARS-CoV2 infection in the hACE2 transgenic mouse model, Bangpungtongseongsan extract was orally administered once a day from 2 days before SARS-CoV2 infection until the day of death. On the day of infection (day 0), the extract of Bangpungtongseongsan of the present invention was orally administered, and 1 hour later, SARS-CoV2 was infected by nasal inoculation at 2,000 pfu/mouse (20 μl/mouse), and daily weight and Body temperature was measured.
그 결과, 도 2에 개시된 바와 같이 본 발명의 방풍통성산 추출물 투여군의 체중은 SARS-CoV2 감염군과 거의 유사한 수준으로 나타났으며, 체온은 SARS-CoV2 감염군의 경우, 6일째 급격하게 체온이 감소하였으나, 본 발명의 방풍통성산 추출물 투여군은 상대적으로 체온을 유지하고 있었고, SARS-CoV2 감염군의 8일 째 생존율이 급격하게 감소하였으나, 본 발명의 방풍통성산 추출물을 투여한 군의 생존율은 약 60% 수준을 유지하였다. 따라서 본 발명의 방풍통성산 추출물은 중증 SARS-CoV2 감염군의 치사율을 낮출 수 있는 것으로 판단하였다.As a result, as shown in FIG. 2, the body weight of the Bangpungtongseong acid extract administration group of the present invention was found to be almost similar to that of the SARS-CoV2 infected group, and the body temperature decreased rapidly on the 6th day in the case of the SARS-CoV2 infected group. However, the Bangpungtongseongsan extract-administered group of the present invention maintained body temperature relatively, and the survival rate of the SARS-CoV2 infected group decreased rapidly on the 8th day, but the survival rate of the Bangpungtongseongsan extract-administered group of the present invention was about 60% level was maintained. Therefore, it was determined that the Bangpungtongseongsan extract of the present invention can lower the mortality rate of severe SARS-CoV2 infected groups.
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220048905A KR102532944B1 (en) | 2022-04-20 | 2022-04-20 | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine mixture extract as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220048905A KR102532944B1 (en) | 2022-04-20 | 2022-04-20 | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine mixture extract as effective component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102532944B1 true KR102532944B1 (en) | 2023-05-17 |
Family
ID=86547163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220048905A KR102532944B1 (en) | 2022-04-20 | 2022-04-20 | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine mixture extract as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102532944B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190003089A (en) * | 2017-06-30 | 2019-01-09 | 한국 한의학 연구원 | Composition for preventing, improving or treating depression and anxiety disorders comprising Bangpungtongseong-san extract as effective component |
| KR20210120733A (en) * | 2020-03-27 | 2021-10-07 | 한국한의약진흥원 | Composition for preventing, ameliorating or treating type 2 diabetes mellitus or dyslipidemia comprising bangpungtongseongsan extract as effective component |
-
2022
- 2022-04-20 KR KR1020220048905A patent/KR102532944B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190003089A (en) * | 2017-06-30 | 2019-01-09 | 한국 한의학 연구원 | Composition for preventing, improving or treating depression and anxiety disorders comprising Bangpungtongseong-san extract as effective component |
| KR20210120733A (en) * | 2020-03-27 | 2021-10-07 | 한국한의약진흥원 | Composition for preventing, ameliorating or treating type 2 diabetes mellitus or dyslipidemia comprising bangpungtongseongsan extract as effective component |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102521871B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102524071B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102532944B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine mixture extract as effective component | |
| KR102532946B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine mixture extract as effective component | |
| KR102527037B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine mixture extract as effective component | |
| KR102540384B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102524075B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102512522B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102529571B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102526488B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102546110B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102526308B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102499066B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102527527B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102524078B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102508944B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102533344B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102524080B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102521837B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102524088B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102506856B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102516639B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102511476B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102537123B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
| KR102497912B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |